Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine ... the second booster restored neutralising antibodies to SARS-CoV-2 to the level seen ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

COVID-19 vaccines used in Brazil are from three different technology platforms. Besides Pfizer's, which contains synthetic RNA from SARS-CoV-2 ... booster dose with an mRNA vaccine such as Moderna ...

The UK has become the first country in the world to authorise an updated COVID-19 booster ... Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS ...

In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA-1018) in healthy adults aged 18 years and older.

Moderna stock has been under pressure amid declining sales of its COVID-19 vaccine. The company projects optimism in its long-term outlook, believing that several pending product approvals can ...

The NHS spring booster campaign will offer jabs to limited groups of vulnerable patients from 1 April. More than 9.7 million ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely ...

The following is a summary of “Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain),” published in the January 2025 issue of Infectious Disease by Montagud et al ...